July 18, 2019 09:51 AM EDT

FDA, EMA advise on risk-based monitoring in clinical trials

Ana Mulero

US and EU officials explained on Wednesday what their respective regulatory agencies look for in clinical trial risk-based monitoring (RBM) and how RBM can impact …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA, EMA advise on risk-based monitoring in clinical trials

Ana Mulero

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

CagriSema’s weight loss data disappointed. What does Novo do next?

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

FDA, EMA ad­vise on risk-based mon­i­tor­ing in clin­i­cal tri­als

Ana Mulero

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

FDA, EMA advise on risk-based monitoring in clinical trials

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

CagriSema’s weight loss data disappointed. What does Novo do next?

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs